Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , , , |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
Elsevier
2019
|